79 related articles for article (PubMed ID: 38528036)
1. Integrative molecular and spatial analysis reveals evolutionary dynamics and tumor-immune interplay of in situ and invasive acral melanoma.
Liu H; Gao J; Feng M; Cheng J; Tang Y; Cao Q; Zhao Z; Meng Z; Zhang J; Zhang G; Zhang C; Zhao M; Yan Y; Wang Y; Xue R; Zhang N; Li H
Cancer Cell; 2024 Jun; 42(6):1067-1085.e11. PubMed ID: 38759655
[TBL] [Abstract][Full Text] [Related]
2. Acral lentiginous melanoma: Basic facts, biological characteristics and research perspectives of an understudied disease.
Basurto-Lozada P; Molina-Aguilar C; Castaneda-Garcia C; Vázquez-Cruz ME; Garcia-Salinas OI; Álvarez-Cano A; Martínez-Said H; Roldán-Marín R; Adams DJ; Possik PA; Robles-Espinoza CD
Pigment Cell Melanoma Res; 2021 Jan; 34(1):59-71. PubMed ID: 32330367
[TBL] [Abstract][Full Text] [Related]
3. Single-cell RNA sequencing unveils tumor heterogeneity and immune microenvironment between subungual and plantar melanoma.
Wang P; Ma Y; Zhao Y; Li Y; Tang C; Wang S; Jin S; Wang J; Zhu M; Xie B; Wang P
Sci Rep; 2024 Mar; 14(1):7039. PubMed ID: 38528036
[TBL] [Abstract][Full Text] [Related]
4. Mapping the single-cell landscape of acral melanoma and analysis of the molecular regulatory network of the tumor microenvironments.
He Z; Xin Z; Yang Q; Wang C; Li M; Rao W; Du Z; Bai J; Guo Z; Ruan X; Zhang Z; Fang X; Zhao H
Elife; 2022 Jul; 11():. PubMed ID: 35894206
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of genetic aberrations and tumor immune microenvironment in primary acral melanoma.
Huang R; Shen G; Ren Y; Zheng K; Wang J; Shi Y; Yin JC; Qin L; Zhang G; Zhao M; Su X; Li L; Wang F; Shao Y; Liu B; Zou Z
J Transl Med; 2023 Feb; 21(1):78. PubMed ID: 36739402
[TBL] [Abstract][Full Text] [Related]
6. Melanomas of the palm, sole, and nailbed: a clinicopathologic study.
Feibleman CE; Stoll H; Maize JC
Cancer; 1980 Dec; 46(11):2492-504. PubMed ID: 7438021
[TBL] [Abstract][Full Text] [Related]
7. Hyperplastic melanocytes with chromosomal aberrations in surrounding skin of subungual melanoma: fluorescence in situ hybridisation analysis using whole-slide digital imaging.
Shojiguchi N; Takai S; Arai E
Histopathology; 2022 Dec; 81(6):808-817. PubMed ID: 36094779
[TBL] [Abstract][Full Text] [Related]
8. Scattered atypical melanocytes with hyperchromatic nuclei in the nail matrix: diagnostic clue for early subungual melanoma in situ.
Park SW; Jang KT; Lee JH; Park JH; Kwon GY; Mun GH; Lee DY; Lee JB; Park KK
J Cutan Pathol; 2016 Jan; 43(1):41-52. PubMed ID: 26423820
[TBL] [Abstract][Full Text] [Related]
9. ERK hyperactivation serves as a unified mechanism of escape in intrinsic and acquired CDK4/6 inhibitor resistance in acral lentiginous melanoma.
Jagirdar K; Portuallo ME; Wei M; Wilhide M; Bravo Narula JA; Robertson BM; Alicea GM; Aguh C; Xiao M; Godok T; Fingerman D; Brown GS; Herlyn M; Elad VM; Guo X; Toska E; Zabransky DJ; Wubbenhorst B; Nathanson KL; Kwatra S; Goyal Y; Ji H; Liu Q; Rebecca VW
Oncogene; 2024 Feb; 43(6):395-405. PubMed ID: 38066089
[TBL] [Abstract][Full Text] [Related]
10. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham MP; Lucas P; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857525
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of EphA3 Expression in Tumour Stromal Cells Suppresses Tumour Growth and Progression.
Vail ME; Farnsworth RH; Hii L; Allen S; Arora S; Anderson RL; Dickins RA; Orimo A; Wu SZ; Swarbrick A; Scott AM; Janes PW
Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760615
[TBL] [Abstract][Full Text] [Related]
12. TIGIT can inhibit T cell activation via ligation-induced nanoclusters, independent of CD226 co-stimulation.
Worboys JD; Vowell KN; Hare RK; Ambrose AR; Bertuzzi M; Conner MA; Patel FP; Zammit WH; Gali-Moya J; Hazime KS; Jones KL; Rey C; Jonjic S; Rovis TL; Tannahill GM; Cruz De Matos GDS; Waight JD; Davis DM
Nat Commun; 2023 Aug; 14(1):5016. PubMed ID: 37596248
[TBL] [Abstract][Full Text] [Related]
13. TIGIT, a novel immune checkpoint therapy for melanoma.
Tang W; Chen J; Ji T; Cong X
Cell Death Dis; 2023 Jul; 14(7):466. PubMed ID: 37495610
[TBL] [Abstract][Full Text] [Related]
14. The Ephrin tyrosine kinase a3 (EphA3) is a novel mediator of RAGE-prompted motility of breast cancer cells.
Talia M; Cirillo F; Spinelli A; Zicarelli A; Scordamaglia D; Muglia L; De Rosis S; Rigiracciolo DC; Filippelli G; Perrotta ID; Davoli M; De Rosa R; Macirella R; Brunelli E; Miglietta AM; Nardo B; Tosoni D; Pece S; De Francesco EM; Belfiore A; Maggiolini M; Lappano R
J Exp Clin Cancer Res; 2023 Jul; 42(1):164. PubMed ID: 37434266
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
